Skip to main content
. Author manuscript; available in PMC: 2015 Aug 11.
Published in final edited form as: Int J Tuberc Lung Dis. 2015 Jan;19(1):21–30. doi: 10.5588/ijtld.14.0263

Figure 1. The relative rate of use (sample unweighted) of classes of respiratory medicines and flu vaccine, by chronic respiratory conditions and by country income.

Figure 1

B in Subjects with reported doctor-diagnosed asthma 

Rate for each class of medicines calculated as (Total number of subjects with symptomatic COPD stage 2 on a particular class of medicines in HIC / Total number of subjects with symptomatic COPD stage 2 on any respiratory medicines in HIC )*100